No title
Quantitative Adverse Outcome Pathways (qAOPs) can support next-generation risk assessment by integrating new approach methods (NAMs) for deriving points of departure. To be useful, a qAOP should be chemical-agnostic. However, existing qAOP studies often pool multichemical data without adequately addressing cross-chemical heterogeneity. Consequently, pathway relationships become obscured by heterog
